Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.45 |
| ▸ | SKP1 | P63208 | 1/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5573222 | 0.83 | MAPT (0.76) | MAPTLMNAALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL1554274 | 0.81 | HTT (0.53) | MAPTLMNAALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL21876057 | 0.81 | MAPT (0.62) | MAPTLMNAALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL4940964 | 0.81 | MAPT (0.56) | MAPTLMNAALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL24990320 | 0.80 | MAPT (0.61) | MAPTLMNAALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL21274054 | 0.80 | MAPT (0.55) | MAPTLMNAALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL13279526 | 0.79 | MAPT (0.64) | MAPTLMNAALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL5542227 | 0.79 | GPR119 (0.65) | MAPTLMNAALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL24963655 | 0.79 | CKS1B (0.53) | MAPTLMNAALDH1A1GPR119MEN1 | |
| SCHEMBL7219737 | 0.79 | MAPT (0.54) | MAPTLMNAALDH1A1GPR119SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688696-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-06-27 | — | — | US | disclosed |
| US-9688696-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-06-27 | — | — | US | disclosed |
| US-20170029440-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-02 | — | — | US | disclosed |
| US-20170029440-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-02 | — | — | US | disclosed |
| US-9499567-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-11-22 | — | — | US | disclosed |
| US-9499567-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-11-22 | — | — | US | disclosed |
| US-20150322088-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-12 | — | — | US | disclosed |
| US-20150322088-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-12 | — | — | US | disclosed |
| EP-2152271-B1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-21 | — | — | EP | disclosed |
| US-9120821-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-09-01 | — | — | US | disclosed |
| US-9120821-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-09-01 | — | — | US | disclosed |
| US-20140350012-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-27 | — | — | US | disclosed |
| US-20140350012-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-27 | — | — | US | disclosed |
| US-8835437-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-09-16 | — | — | US | disclosed |
| US-8835437-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-09-16 | — | — | US | disclosed |
| US-20100216809-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-26 | — | — | US | disclosed |
| US-20100216809-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-26 | — | — | US | disclosed |
| WO-2008148840-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-11 | — | — | WO | disclosed |
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | SLC1A1, SLC6A7, SLC1A2 | MAPT 762/4885LMNA 4248/4885ALDH1A1 1291/4885 |
| US-20100216809-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, DGAT2, DLAT | MAPT 2039/4885LMNA 2272/4885ALDH1A1 488/4885 |
| US-20170029440-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, PAOX, DGAT2 | MAPT 2270/4885LMNA 2124/4885ALDH1A1 590/4885 |
| US-20140350012-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, PAOX, NNT | MAPT 2026/4885LMNA 2149/4885ALDH1A1 629/4885 |
| US-20150322088-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, PAOX, DGAT2 | MAPT 2270/4885LMNA 2124/4885ALDH1A1 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.